Literature DB >> 28284487

Toll-like receptors as a key regulator of mesenchymal stem cell function: An up-to-date review.

Solmaz Shirjang1, Behzad Mansoori2, Saeed Solali3, Majid Farshdousti Hagh4, Karim Shamsasenjan5.   

Abstract

Understanding the role of toll-like receptors (TLRs) in the immunomodulation potential, differentiation, migration, and survival of mesenchymal stem cells (MSCs) is absolutely vital to fully exploiting their MSC-based therapeutic potential. Furthermore, through recognition of exogenous or endogenous ligands produced upon injury, TLRs have been linked to allograft rejection and maintenance of chronic inflammatory diseases, including Crohn's disease, rheumatoid arthritis. Characterizing the effect of TLRs in biological control of MSCs fate and function could improve our knowledge about the MSC-based cell therapy and immunotherapy. In this paper, we outline the impacts of TLR activation and mechanisms on MSCs immunomodulatory functions, differentiation, migration, and survivability. Moreover, we indicate that the expression patterns of TLRs in MSCs from different sources.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Immunology; Mechanism; Mesenchymal stem cell; Therapeutic use; Toll-like receptor

Mesh:

Substances:

Year:  2016        PMID: 28284487     DOI: 10.1016/j.cellimm.2016.12.005

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  36 in total

1.  MG53 attenuates lipopolysaccharide-induced neurotoxicity and neuroinflammation via inhibiting TLR4/NF-κB pathway in vitro and in vivo.

Authors:  Fangxia Guan; Xinkui Zhou; Peng Li; Yaping Wang; Ming Liu; Fangfang Li; Yuanbo Cui; Tuanjie Huang; Minghao Yao; Yanting Zhang; Jianjie Ma; Shanshan Ma
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-06-29       Impact factor: 5.067

Review 2.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

3.  In vitro Exposure to Inflammatory Mediators Affects the Differentiation of Mesenchymal Progenitors.

Authors:  S Marsh; T Constantin-Teodosiu; V Chapman; V Sottile
Journal:  Front Bioeng Biotechnol       Date:  2022-06-22

Review 4.  The Effect of Inhalant Organic Dust on Bone Health.

Authors:  Joseph M Carrington; Jill A Poole
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-22       Impact factor: 4.806

5.  Therapeutic Potential of Extracellular Vesicles for Sepsis Treatment.

Authors:  Stephanie M Kronstadt; Alex E Pottash; Daniel Levy; Sheng Wang; Wei Chao; Steven M Jay
Journal:  Adv Ther (Weinh)       Date:  2021-04-29

6.  Toll-Like Receptor 4 Mediates Methamphetamine-Induced Neuroinflammation through Caspase-11 Signaling Pathway in Astrocytes.

Authors:  Si-Hao Du; Dong-Fang Qiao; Chuan-Xiang Chen; Si Chen; Chao Liu; Zhoumeng Lin; Huijun Wang; Wei-Bing Xie
Journal:  Front Mol Neurosci       Date:  2017-12-12       Impact factor: 5.639

Review 7.  Meaning of the Solid and Liquid Fascia to Reconsider the Model of Biotensegrity.

Authors:  Bruno Bordoni; David Lintonbon; Bruno Morabito
Journal:  Cureus       Date:  2018-07-05

8.  A New Concept of Biotensegrity Incorporating Liquid Tissues: Blood and Lymph.

Authors:  Bruno Bordoni; Fabiola Marelli; Bruno Morabito; Roberto Castagna
Journal:  J Evid Based Integr Med       Date:  2018 Jan-Dec

9.  Augmenting emergency granulopoiesis with CpG conditioned mesenchymal stromal cells in murine neutropenic sepsis.

Authors:  Julie Ng; Fei Guo; Anna E Marneth; Sailaja Ghanta; Min-Young Kwon; Joshua Keegan; Xiaoli Liu; Kyle T Wright; Baransel Kamaz; Laura A Cahill; Ann Mullally; Mark A Perrella; James A Lederer
Journal:  Blood Adv       Date:  2020-10-13

10.  High-mobility group box 1 facilitates migration of neural stem cells via receptor for advanced glycation end products signaling pathway.

Authors:  Xin Xue; Xingxing Chen; Weili Fan; Guan Wang; Liang Zhang; Zongfeng Chen; Peng Liu; Mingyong Liu; Jianhua Zhao
Journal:  Sci Rep       Date:  2018-03-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.